Cardlytics, Inc. (CDLX)

From the record

Cardlytics, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2026-06-03) (its current reports).

From the record

Cardlytics, Inc.'s 10 filed years say what it did: revenue went from $113 million in fiscal 2016 to $233 million in fiscal 2025, up 8.4% a year; it rose in 6 of 9 years; the deepest fall was 25% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Cardlytics, Inc.'s diluted share count grew about 16.7% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 16 sales and 2 purchases of their own stock on the open market in the year to 2026-10-02, buying about $129 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Cardlytics, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 102 cents per dollar of assets, and net share issuance: its share count grew 9.8% over the year (the filed statements).

From the record

Cardlytics, Inc.'s standing among 73 graded names in its industry family: revenue of $233 million in fiscal 2025 ranks in the bottom 35% by size; a net margin of -44.4% ranks in the bottom 23%; revenue growth of -7.9% a year over the last 3 filed years ranks in the bottom 19% (its annual reports).

From the record

Cardlytics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Gupta, Amit (Chief Executive Officer, as filed), filing under that title since 2024-08-22, 2.2 years (bottom 26% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 3.2 years (bottom 23%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 14%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Cardlytics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $49 million against debt of $213 million leaves -57.4% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 3.8% of revenue (bottom 48%); research spending of 17% of revenue (top 45%) (its annual report).

From the record

Cardlytics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -7.9% a year over the last three filed years against 8.4% over all 10, slowing (bottom 24% of its family); the newest year grew -16.2% (bottom 8%); research spending grew -9.9% a year (bottom 23%); capital spending grew -25.7% a year (bottom 19%) (its annual reports). Cardlytics, Inc. reported 2 lines of business in fiscal 2025: Cardlytic Direct at $212 million (91%), Bridg Acquisition at $21 million (9%); 0 of 2 grew against the year before (its annual report).

From the record

Cardlytics, Inc.'s newest year against its own record: revenue of $233 million in fiscal 2025 came in 13.2% below the $269 million its prior three years' pace pointed to (bottom 12% of its family); net income of $103 million against a prior three-year average of $263 million (top 42%); a net margin of -44.4% against -89.1% before (top 10%) (its annual reports).